Camrelizumab with famitinib after cervical cancer surgery
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, camrelizumab and famitinib, given after surgery to remove cervical cancer. The goal is to see if this treatment can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 75 years old.
- You have not had any previous cancer treatment like chemotherapy, radiation, or other drugs.
- Your tumor has a PD-L1 score of at least 1 (CPS ≥ 1).
- You have at least one tumor that can be measured on a scan.
- Your cancer type is squamous cell, adenosquamous, or adenocarcinoma.
- Your cancer stage is IA, IB1-2, IIA1, IB3, or IIA2 (according to FIGO 2018).
- You are in good physical condition (ECOG score 0 or 1) and your organs are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests whether giving chemotherapy combined with camrelizumab (a drug that helps the immune system fight cancer) before surgery can help women with early-stage cervical cancer who want to preserve their fertility. It is for patients whose tumors show a protein called PD-L1.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
This trial tests a combination of two drugs—camrelizumab (an immunotherapy) and famitinib (a targeted therapy)—for people with rare head and neck tumors that cannot be removed by surgery or have spread. It may be an option if you have not had a prior PD-1 inhibitor and have had at most one prior systemic treatment.
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.